ESC Congress 2022 (Photo by Kyle LaHucik)
August 28, 2022 03:36 AM EDTUpdated August 29, 06:17 AM
R&D
Pharma

#ESC22: Bay­er's fac­tor XIa in­hibitor miss­es ef­fi­ca­cy marks in 2 PhII stud­ies but com­pa­ny dives straight in­to PhI­II

Kyle LaHucik

Senior Reporter

BARCELONA — Bay­er’s fac­tor XIa in­hibitor didn’t clear the hur­dle in cer­tain pri­ma­ry ef­fi­ca­cy marks in two Phase II clin­i­cal stud­ies, tri­al in­ves­ti­ga­tors said Sun­day morn­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times